Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction

Abstract

Inhibiting the PD-1/PD-L1 protein–protein interaction is a key immunotherapy for cancer. Antibodies dominate the clinical space but are costly, with limited applicability and immune side effects. We developed a photo-controlled azobenzene peptide that selectively inhibits the PD-1/PD-L1 interaction when in the cis isomer only. Activity is demonstrated in in vitro and cellular assays.